# Antimicrobial target identification by Genome Scale Metabolic Modelling

Pareena Verma

September 19, 2024







Antimicrobial target identification by Genome

/17

• Identify metabolic responses of resistant bacteria to antibiotic challenge.

• Develop methods to integrate TraDIS data into metabolic model.

• Identify potential drug targets i.e., ezymes involved in identified metabolic pathways.

A (10) A (10) A (10)

• Identify metabolic responses of resistant bacteria to antibiotic challenge.

• Develop methods to integrate TraDIS data into metabolic model.

 Identify potential drug targets i.e., ezymes involved in identified metabolic pathways.

- Diarrhea in the postweaning period due to ETEC is an economically relevant disease in pig production worldwide.
- Macrolides are widely used in pig farming but are ineffective against ETEC due to outer membrane impermeability.
- Macrolides inhibit bacterial protein synthesis by binding to 50S subunit of ribosome, thereby inhibiting protein synthesis.
- Objective : Identify intrinsic resistance mechanisms that can be exploited to re-sensitise ETEC to tilmicosin (an antibiotic of macrolide class) treatment.

- Diarrhea in the postweaning period due to ETEC is an economically relevant disease in pig production worldwide.
- Macrolides are widely used in pig farming but are ineffective against ETEC due to outer membrane impermeability.
- Macrolides inhibit bacterial protein synthesis by binding to 50S subunit of ribosome, thereby inhibiting protein synthesis.
- Objective : Identify intrinsic resistance mechanisms that can be exploited to re-sensitise ETEC to tilmicosin (an antibiotic of macrolide class) treatment.

< 口 > < 同 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ >

# TraDIS : **Tra**nsposon **D**irected Insertion Site **S**equencing

- Input libraries were constructed with >1 mn mutants.
- Each mutant in library had atleast 1 random transposon insertion in it rendering the gene non-functional.
- Mutant libraries were grown in 2 conditions:
  - Control without antibiotic
  - Test with antibiotic
- Libraries were sequenced and sequence reads analysed by Biotradis software pipeline.
- comparison tradis : calculates read count differences (logFC) in 2 conditions and gives conditionally essential genes.

# TraDIS : **Tra**nsposon **D**irected Insertion Site **S**equencing

- Input libraries were constructed with >1 mn mutants.
- Each mutant in library had atleast 1 random transposon insertion in it rendering the gene non-functional.
- Mutant libraries were grown in 2 conditions:
  - Control without antibiotic
  - Test with antibiotic
- Libraries were sequenced and sequence reads analysed by Biotradis software pipeline.
- comparison tradis : calculates read count differences (logFC) in 2 conditions and gives conditionally essential genes.

# Experiment - Tn Mutant Library construction



September 19, 2024

э

### **Experiment - TraDIS**



・ロト ・ 四ト ・ ヨト ・ ヨト

э

#### 26 genes were implicated in survival under antibiotic treatment :

- 8 genes : metabolic
- 2 genes : efflux pumps
- 9 genes : outer membrane assembly
- 3 genes : ribosome
- 4 genes : miscellaneous

4 A N

26 genes were implicated in survival under antibiotic treatment :

- 8 genes : metabolic
- 2 genes : efflux pumps
- 9 genes : outer membrane assembly
- 3 genes : ribosome
- 4 genes : miscellaneous

Model property	<i>E. coli</i> MG1655
Reactions	1542
Metabolites	1443
External metabolites	92
Biomass transporters	44
Reactions involved in biomass production	256
C source	GLC
S source	SO <sub>4</sub>
N source	$NH_3$

イロト イヨト イヨト イヨト

### TraDIS genes <> Metabolic reactions

Gene	Enzyme	Reaction
gmhB	$\beta$ -HBP	RXN0-4361
<i>waa</i> F	Hepll	RXN0-5061
<i>waa</i> P	LPS core hepl kinase	RXN-22461 RXN0-5121
lpxM rfaD pgm kdsC	myr-transferase AGME Phosphoglucomutase KDO-8P phosphatase	MYRISTOYLACYLTRAN-RXN 5.1.3.20-RXN PHOSPHOGLUCMUT-RXN KDO-8PPHOSPHAT-RXN
<i>waa</i> Q	HepIII	RXN-22462 RXN0-5122

# Pathway involved



イロト イヨト イヨト イヨト

æ

10/17

#### Knockout analysis - LP

min 
$$\sum_{i=1}^{n} |v_i|$$
  
subject to  $\begin{cases} \mathbf{Nv} = \mathbf{0}, \\ v_{LPS} = 1, \\ v_{gene} = \mathbf{0} \end{cases}$ 

æ

イロト イヨト イヨト イヨト

min 
$$\sum_{i=1}^{n} |v_i|$$
  
subject to  $\begin{cases} \mathbf{Nv} = \mathbf{0}, \\ v_{LPS} = 1, \\ v_{gene} = \mathbf{0} \end{cases}$ 

Pareena Verma

æ

イロト イヨト イヨト イヨト

(1)

## Knockout analysis

Gene	Reaction/BioCyc-ID	Knockout impact (LP Solution)
<i>gmh</i> B waaF	RXN0-4361 RXN0-5061	No Solution No Solution
<i>waa</i> P	RXN-22461 RXN0-5121	Solution Solution
lp <i>x</i> M rfaD pgm kdsC	MYRISTOYLACYLTRAN-RXN 5.1.3.20-RXN PHOSPHOGLUCMUT-RXN KDO-8PPHOSPHAT-RXN	No Solution No Solution No Solution No Solution
<i>waa</i> Q	RXN-22462 RXN0-5122	Solution Solution

イロト イヨト イヨト イヨト

æ

• Minimal set of reactions which cannot be further decomposed into simpler pathways in a metabolic network at steady-state.

• Set of reactions in an EM is unique.

• Net metabolic behaviour of a system can always be expressed as a linear combination of its EMs.

A (10) A (10) A (10)

 Minimal set of reactions which cannot be further decomposed into simpler pathways in a metabolic network at steady-state.

• Set of reactions in an EM is unique.

 Net metabolic behaviour of a system can always be expressed as a linear combination of its EMs.

#### Elementary Mode analysis



#### **Elementary Mode analysis**



• A metabolic network was identified in response to macrolide treatment in resistant *E. coli*.

 It is mainly associated with lipopolysaccharide (LPS, component of cell wall) synthesis.

• The enzymes present in the network can be potential drug targets.

(I) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1)) < ((1))

#### Acknowledgements







Quadram Institute

The project has received funding from the EU's Horizon 2020 research and innovation programme under the Marie Sklodowska Curie Grant Agreement no. 956154.

Pareena Verma

Antimicrobial target identification by Genome

September 19, 2024

7/17